Abstract
Natalizumab treatment of multiple sclerosis (MS) is associated with a risk of developing progressive multifocal leukoencephalopathy (PML), a rare oppo......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
